Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Judging Obesity Drugs: Can Patient-Focused Statistics Bring Simplicity, Clarity?

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The odds ratio would be a simpler way to look at an obesity drug’s success in promoting 5% weight loss than the current three-step process, FDA’s statistical reviewer said in her assessment of Belviq’s efficacy.

You may also be interested in...



Arena Finds Antidote For Belviq’s Theoretical Risk Of Valvulopathy In Mechanistic Studies

Additional preclinical studies provided FDA with reassurance during a second-cycle review that lorcaserin was unlikely to trigger the valvular heart disease associated with dexfenfluramine and fenfluramine.

New Paradigm Would Open More Avenues To Obesity Drug Approval

Assessments of obesity drugs should look at their effects in patients grouped by health status and FDA should expand the universe of secondary endpoints available to assess benefits, a group of stakeholders says.

Orexigen On Quicker-Than-Expected Pace To Obtain Data Needed To Re-File NDA For Contrave

During its second quarter earnings call, the biotech said it sees recent FDA approvals of two other obesity drugs as a positive for its own prospects, but it is re-engaging with the agency on why it must perform a cardiovascular-outcomes trial prior to approval.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS004960

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel